EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, ...
Beam Therapeutics (BEAM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...
New data shed light on the risks for complications when female patients with sickle cell disease undergo fertility ...